STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) — Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ: PRLD) (“Prelude” or the “Company”) on behalf of the Company’s investors.
The objective of this investigation is to determine whether Prelude’s board of directors (the “Board”) violated fiduciary duties owed to Prelude stockholders in connection with certain provisions in Prelude’s bylaws that may have the effect of entrenching the Board and insulating Prelude’s directors from being held accountable by Prelude stockholders.
Prelude stockholders are encouraged to contact Abbott Cooper PLLC by calling (475) 333-0674, emailing ac@abbottlawyer.com or visiting our website at www.abbottlawyer.com for additional information about this investigation as well as their legal rights and options.
Abbott Cooper PLLC is dedicated to shareholders’ rights and empowering shareholders through strategic counsel and legal advocacy. For additional information about Abbott Cooper PLLC, please visit www.abbottlawyer.com.
CONTACT:
Abbott Cooper PLLC
Abbott Cooper
(475) 333-0674
www.abbottlawyer.com
Attorney advertising. Prior results do not guarantee a similar outcome.
- SEALSQ Organizes French Quantum and Space Day: Leading Experts in Quantum, Post-Quantum, and Space Security Gather near Marseille for a Unique Technology Showcase - April 28, 2025
- Endeavor Bancorp Reports Net Income of $1.4 Million for the First Quarter of 2025; Highlighted by Loan and Deposit Growth and Net Interest Margin Expansion - April 28, 2025
- Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - April 28, 2025
